drugset / Trial / NCT04423029
A Study of DF6002 Alone and in Combination With Nivolumab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Timeline
- Start
- 2020-07-13
- Primary completion
- 2025-11-26
- Completion
- 2025-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DF6002 | Unknown | — | Subcutaneous |
| Subject | Nivolumab | Monoclonal antibody | — | — |